Pacira BioSciences Statistics
Total Valuation
PCRX has a market cap or net worth of $1.14 billion. The enterprise value is $1.29 billion.
Important Dates
The next estimated earnings date is Tuesday, May 6, 2025, after market close.
| Earnings Date | May 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PCRX has 46.28 million shares outstanding. The number of shares has decreased by -11.03% in one year.
| Current Share Class | 46.28M |
| Shares Outstanding | 46.28M |
| Shares Change (YoY) | -11.03% |
| Shares Change (QoQ) | +6.29% |
| Owned by Insiders (%) | 0.92% |
| Owned by Institutions (%) | 108.15% |
| Float | 43.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 8.49 |
| PS Ratio | 1.63 |
| Forward PS | 1.50 |
| PB Ratio | 1.46 |
| P/TBV Ratio | 3.24 |
| P/FCF Ratio | 6.38 |
| P/OCF Ratio | 6.02 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 7.34, with an EV/FCF ratio of 7.24.
| EV / Earnings | n/a |
| EV / Sales | 1.85 |
| EV / EBITDA | 7.34 |
| EV / EBIT | 13.27 |
| EV / FCF | 7.24 |
Financial Position
The company has a current ratio of 2.40, with a Debt / Equity ratio of 0.82.
| Current Ratio | 2.40 |
| Quick Ratio | 1.93 |
| Debt / Equity | 0.82 |
| Debt / EBITDA | 3.33 |
| Debt / FCF | 3.57 |
| Interest Coverage | 5.89 |
Financial Efficiency
Return on equity (ROE) is -12.08% and return on invested capital (ROIC) is 4.24%.
| Return on Equity (ROE) | -12.08% |
| Return on Assets (ROA) | 3.90% |
| Return on Invested Capital (ROIC) | 4.24% |
| Return on Capital Employed (ROCE) | 7.85% |
| Revenue Per Employee | $887,299 |
| Profits Per Employee | -$126,025 |
| Employee Count | 790 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 2.19 |
Taxes
In the past 12 months, PCRX has paid $36.45 million in taxes.
| Income Tax | 36.45M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.15% in the last 52 weeks. The beta is 0.71, so PCRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.71 |
| 52-Week Price Change | -8.15% |
| 50-Day Moving Average | 24.62 |
| 200-Day Moving Average | 19.72 |
| Relative Strength Index (RSI) | 51.22 |
| Average Volume (20 Days) | 1,152,421 |
Short Selling Information
The latest short interest is 5.93 million, so 12.82% of the outstanding shares have been sold short.
| Short Interest | 5.93M |
| Short Previous Month | 5.93M |
| Short % of Shares Out | 12.82% |
| Short % of Float | 13.65% |
| Short Ratio (days to cover) | 6.30 |
Income Statement
In the last 12 months, PCRX had revenue of $700.97 million and -$99.56 million in losses. Loss per share was -$2.15.
| Revenue | 700.97M |
| Gross Profit | 448.96M |
| Operating Income | 97.57M |
| Pretax Income | 100.55M |
| Net Income | -99.56M |
| EBITDA | 176.36M |
| EBIT | 97.57M |
| Loss Per Share | -$2.15 |
Full Income StatementBalance Sheet
The company has $484.62 million in cash and $638.85 million in debt, giving a net cash position of -$154.24 million or -$3.33 per share.
| Cash & Cash Equivalents | 484.62M |
| Total Debt | 638.85M |
| Net Cash | -154.24M |
| Net Cash Per Share | -$3.33 |
| Equity (Book Value) | 778.35M |
| Book Value Per Share | 16.83 |
| Working Capital | 435.21M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $189.39 million and capital expenditures -$10.64 million, giving a free cash flow of $178.75 million.
| Operating Cash Flow | 189.39M |
| Capital Expenditures | -10.64M |
| Free Cash Flow | 178.75M |
| FCF Per Share | $3.86 |
Full Cash Flow StatementMargins
Gross margin is 64.05%, with operating and profit margins of 13.92% and -14.20%.
| Gross Margin | 64.05% |
| Operating Margin | 13.92% |
| Pretax Margin | -9.00% |
| Profit Margin | -14.20% |
| EBITDA Margin | 25.16% |
| EBIT Margin | 13.92% |
| FCF Margin | 25.50% |
Dividends & Yields
PCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 11.03% |
| Shareholder Yield | n/a |
| Earnings Yield | -8.73% |
| FCF Yield | 15.67% |
Dividend DetailsAnalyst Forecast
The average price target for PCRX is $30.11, which is 22.00% higher than the current price. The consensus rating is "Buy".
| Price Target | $30.11 |
| Price Target Difference | 22.00% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 9.90% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PCRX has an Altman Z-Score of 1.65 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.65 |
| Piotroski F-Score | 6 |